Roche announced today that the European Commission has approved its innovative drug Mircera to treat anaemia associated with chronic kidney disease (CKD). The approval of Mircera results in a single ...

Roche announced today that the U.S. Food and Drug Administration (FDA) has approved Mircera (methoxy polyethylene glycol-epoetin beta) for the treatment of anaemia associated with chronic kidney ...

IN 2015 VIFOR PHARMA (FORMERLY A COMPANY OF GALENICA GROUP) ENTERED INTO AN EXCLUSIVE LICENSE AGREEMENT WITH ROCHE FOR THE COMMERCIALISATION OF ITS MEDICINE MIRCERA ® in the US. MIRCERA ® IS A ...

The approval was based on an open-label, multiple dose, multicenter, dose-finding study in 64 pediatric patients with CKD who were on hemodialysis and who had stable hemoglobin levels while previously ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved Mircera for the treatment of pediatric patients 5 to 17 years of age on hemodialysis who are ...

A big plus for Roche today after the European Commission issued a final positive decision for its once- or twice-monthly anaemia drug Mircera for use in chronic kidney disease patients that is valid ...

Data from the analysis of six major trials for the innovative new renal anaemia treatment MIRCERA, have shown that it effectively corrects and maintains haemoglobin levels in chronic kidney disease ...

-- Findings Illustrate Role of Innovative New Treatment in Population Most Affected by Chronic Kidney Disease A new Roche Phase III analysis shows once-monthly MIRCERA, a continuous erythropoietin ...

Please provide your email address to receive an email when new articles are posted on . It is an exciting time in the treatment of renal anemia, with several new therapies recently launched or ...

Switzerland’s Roche has suffered a dent to its stock after revealing that it has temporarily suspended recruitment into a Phase II dose-finding study with its new anaemia drug Mircera. Switzerland’s ...

less than 0.5 g/dL from start of the trial in patients over age 65 with a simplified dosing schedule. The data were presented today at the World Congress of Nephrology (WCN) in Rio de Janeiro. "These ...